

Electronic Supplementary Information

Tripodal-Oxazoline-Based Homochiral Coordination Cages with Internal Binding Sites

Jeongryul Kim,^a Dowook Ryu,^a Yoshihisa Sei,^b Kentaro Yamaguchi^b and Kyo Han Ahn*^a

^a Department of Chemistry and Center for integrated Molecular Systems, Division of Molecular and Life Science, Pohang University of Science and Technology, San 31, Hyoja-dong, Pohang 790-784, Republic of Korea; Fax: +82) 54 279 3399; Tel: +82) 54 279 2105. E-mail: ahn@postech.ac.kr

^b Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido, Sanuki-city, Kagawa, 769-2193 Japan. Fax: 81 87 894 0181; Tel: 81 87 894 5111; E-mail: yamaguchi@kph.bunri-u.ac.jp

1. General Methods


All commercial reagents are of ACS reagent grade and used as supplied. DMF and CH₂Cl₂ were dried over 4 Å molecular sieves and CaH₂, respectively, and distilled before use. Metal precursors were prepared following the established procedures.¹⁻³ Column chromatography was carried out on Merck silica gel 60 (230-400 mesh). Melting points were obtained with an electrothermal capillary apparatus and were uncorrected. Optical rotations were measured using Rudolph Research Autopol III digital polarimeter using a sodium lamp (D line, 589 nm) and are reported in degrees with concentration in unit of 10 mg mL⁻¹. ¹H and ¹³C spectra were recorded using a Bruker AMX 300 or DRX 500 spectrometer and all chemical shifts were reported as δ in parts per million (ppm) downfield from tetramethylsilane (δ = 0.0). ³¹P NMR spectra were recorded using a Bruker XP200 (81 MHz) spectrometer, and all chemical shifts were reported in ppm relative to external 80% H₃PO₄ at 0.00 ppm. ¹⁹F NMR spectra were recorded using a Bruker XP200 (188.3 MHz) spectrometer, and all chemical shifts were reported relative to external CFCl₃ at 0.00 ppm. Mass spectral analysis was recorded on Jeol JMS-AX505WA and is reported in units of mass to charge (*m/z*). CSI mass spectra were recorded on a QSTAR XL Hybrid LC/MS/MS System. Elemental

analyses and HRMS were performed by the Korea Basic Science Institute at Kyung-Pook Branch Analytical Laboratory.

Reference:

1. S. Fallis, G. K. Anderson and N. P. Rath, *Organometallics*, 1991, **10**, 3180-3184.
2. P. J. Stang, D. H. Cao, S. Saito and A. M. Arif, *J. Am. Chem. Soc.* 1995, **117**, 6273-6283.
3. M. Fujita, J. Yazaki and K. Ogura, *J. Am. Chem. Soc.* 1990, **112**, 5645-5647.


2. Syntheses and Characterization of compounds 1a and 1b.




The Synthesis of intermediates **6** has been followed by the procedure reported in the reference 4 in the main paper. More specifically, compounds **5** and **6** have been used in the synthesis of other tripodal receptors, and their characterization data are included in a submitted paper.

2-[(3,5-Bis{[4-(3-hydroxyphenyl)-4,5-dihydrooxazol-2-yl]methyl}-2,4,6-triethyl-phenyl)methyl-4-(3-hydroxyphenyl)-4,5-dihydrooxazole-4-yl]phenoxy}methyl-4-pyridine (1b). NaH (350 mg, 14.55 mmol) was added in small portions into a solution of **6b** (1.0 g, 1.46 mmol) in dry DMF (20 mL). After hydrogen gas evolution is subsided, the mixture was stirred at room temperature for 30 min. A solution of 4-bromomethylpyridine (1.84 g, 7.27 mmol) in CH_2Cl_2 (100 mL) was introduced into the reaction mixture using a syringe. The resulting mixture was stirred at room temperature for 24 h, and it was poured into an Erlenmeyer flask containing a mixture of water/dichloromethane. The organic layer was separated, washed with brine, dried over anhydrous MgSO_4 , and concentrated to dryness. The residue was purified by column

chromatography (MeOH:EtOAc, 3:7) to afford the desired pyridyl-tris(oxazoline) **1b** as white powders (0.75 g, 54%). (4-Bromomethylpyridine was freshly prepared before use by the following method: A saturated aqueous Na₂CO₃ solution was added to a stirred solution of 4-bromomethylpyridine·HBr (1.84 g, 7.27 mmol) in distilled water (50 ml) at 0 °C, at such a rate to maintain the temperature <5 °C and to reach pH ~7. Then, 4-bromomethylpyridine was extracted with dichloromethane, dried over anhydrous MgSO₄, and filtered. The filtrate (100 ml) was used without further purification.) **1b**: mp 109-101 °C; [α]_D²¹ = +2.5 (*c* = 1.0, CH₂Cl₂); ¹H NMR (300 MHz, CD₂Cl₂) δ 8.59 (d, *J* = 5.7 6H), 7.36 (d, *J* = 5.6 6H), 7.24 (dd, *J* = 7.9, 7.5 3H), 6.88-6.84 (m, 9H), 5.13 (dd, *J* = 9.1, 8.4 3H), 5.07 (s, 6H), 4.60 (dd, *J* = 9.4, 8.6 3H), 4.03 (dd, *J* = 8.4, 7.9 3H), 3.85 (s, 6H), 2.94 (q, *J* = 7.5 6H), 1.24 (t, *J* = 7.5 9H); ¹³C NMR (75 MHz, CD₂Cl₂) δ 167.9, 159.0, 150.5, 146.6, 145.1, 142.6, 130.7, 130.2, 121.9, 120.0, 114.0, 113.5, 75.1, 70.0, 68.6, 29.1, 23.9, 14.9; MS (FAB) *m/z* (rel. intensity) 962 (M+1, 100), 871 (12), 735 (8); HRMS (FAB) calcd. for C₆₀H₆₁O₆N₆ 961.4653, found 961.4650.



2-[(3,5-Bis{[4-(3-hydroxyphenyl)-4,5-dihydrooxazol-2-yl]methyl}-2,4,6-trimethyl-phenyl)methyl-4-(3-hydroxyphenyl)-4,5-dihydrooxazole-4-yl]phenoxy}methyl-4-pyridine (1a**).** This compound was synthesized similarly as above starting from compound **5a**. The crude product was purified by column chromatography (MeOH:EtOAc, 3:7) to afford **1a** in 63% yield as white solids: mp 92-94 °C; ¹H NMR (300 MHz, acetone-d₆) δ 8.48 (d, *J* = 5.3 6H), 7.44 (d, *J* = 4.8 6H), 7.20 (dd, *J* = 8.3, 7.6 3H), 6.89-6.79 (m, 9H), 5.06 (s, 9H), 4.59 (dd, *J* = 9.4, 8.6 3H), 3.99 (dd, *J* = 8.7, 8.1 3H), 3.86 (s, 6H), 2.45 (s, 9H); ¹³C NMR (75 MHz, acetone-d₆) δ 170.3, 160.2, 150.4, 149.5, 145.6, 137.3, 132.0, 131.2, 123.4, 120.8, 115.2, 114.4, 76.4, 70.1, 69.1, 30.8, 17.8; MS (FAB) *m/z* (rel. intensity) 919 (M+1, 100), 846 (41); HRMS (FAB) calcd. for C₅₇H₅₄N₆O₆ 918.4105, found 918.4112.



Cage 2b. This complex was assembled by mixing tripodal oxazoline **1b** with *trans*-Pd(OTf)₂(PEt₃)₂ in a molar ratio of 2:3 in CH₂Cl₂ at room temperature for 5 min. Removal of the solvent in vacuo afforded the desired cage in a quantitative yield. The

peak at 1.2 ppm in the ^1H NMR spectrum is owing to the presence of “free” Et_3P because a slight excess amount of the palladium source was used:






Fig. S1 ^{31}P NMR spectra obtained for a mixture of **1b** and $\text{Pd}(\text{PEt}_3)_2(\text{OTf})_2$ in CD_2Cl_2 at 25°C with different molar ratios: (a) at a molar ratio of 2:3; (b) when more than 1.5 equiv of the Pd source was added to the solution (a).

(a)



(b)



(c)




Fig. S2 (a) CSI-MS spectrum for the cage **2b**, (b) an enlarged part of the m/z range 3500-4100, (c) an enlarged part of the m/z range 1000-1800. Experimental conditions: acceleration voltage, 5.0 kV; needle voltage, 2.8 kV; orifice voltage, 202 V; ring lens voltage, 254 V; spray temperature, 20 °C; resolution: 1000; flow rate, 1.0 mL/h; solvent: CH₂Cl₂.




Fig. S3 A selected region of the VT-NMR experimental data for the cage **2b** (from the bottom, taken at -40, -20, -5, 10, 25, 40 °C)




Fig. S4 The disassembly experiment of the cage **2b** in the presence of Et_3N : (a) cage **2b** as single component, (b) partial disassembly into its free ligand **1b** after addition of 0.7 equiv of Et_3N , (c) complete disassembly into **1b** in the presence of excess Et_3N (10 equiv) at 300K. (■: cage, □: ligand, ▲: solvent, △: Et_3N)




Fig. S5 Self-assembly of **1a** and $[\text{Pd}(\text{OTf})_2(\text{PET}_3)_2]$, monitored by ^1H NMR in acetone- d_6 at 25 °C: (a) free **1a**; (b) a mixture of $[\mathbf{1a}]/[\text{Pd}(\text{OTf})_2(\text{PET}_3)_2]$ in a ratio of 2/1; (c) in a ratio of 1/1; (d) in a ratio of 2/3.




Fig. S6 ^1H NMR spectral change of the cage **2b** upon gradual addition of $\text{NH}_4\cdot\text{PF}_6$ in CD_2Cl_2 at 25°C : (a) free cage **2b**, (b) 0.5 equiv. of the guest added, (c) 1.0 equiv. of the guest added, (d) 2.0 equiv. the guest added (Note: a small amount of acetone was used to dissolve the guest).




Fig. S7 ^1H NMR spectral change of cage **2b** upon addition of enantiomeric and racemic α -phenylethylammonium perchlorate (The guest methyl group indicated in the box is enlarged and shown at the right side): (a) $[\mathbf{2b}]/[(R)\text{-guest}] = 1/2$; (b) $[\mathbf{2b}]/[(S)\text{-guest}] = 1/2$; (c) $[\mathbf{2b}]/[\text{racemic guest}] = 1/4$.